Musa Tariq Sells 1,951 Shares of Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 1,951 shares of the stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $131.16, for a total transaction of $255,893.16. Following the sale, the director directly owned 11,048 shares of the company’s stock, valued at $1,449,055.68. The trade was a 15.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Tuesday, June 16th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $130.19, for a total transaction of $15,102.04.
• On Monday, May 18th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $95.96, for a total transaction of $11,131.36.
• On Thursday, April 16th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $84.83, for a total transaction of $9,840.28.

Guardant Health Stock Up 1.6%

Shares of Guardant Health stock traded up $2.00 during trading on Tuesday, reaching $130.83. 1,931,570 shares of the stock were exchanged, compared to its average volume of 2,130,785. The firm has a market cap of $17.35 billion, a price-to-earnings ratio of -38.59 and a beta of 1.61. Guardant Health, Inc. has a 1 year low of $40.35 and a 1 year high of $135.00. The stock’s fifty day moving average is $108.07 and its 200 day moving average is $103.04.

Hedge Funds Weigh In On Guardant Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Allworth Financial LP boosted its holdings in shares of Guardant Health by 19.5% during the 3rd quarter. Allworth Financial LP now owns 844 shares of the company’s stock valued at $53,000 after buying an additional 138 shares in the last quarter. Eastern Bank boosted its stake in Guardant Health by 6.9% during the fourth quarter. Eastern Bank now owns 2,160 shares of the company’s stock worth $221,000 after acquiring an additional 139 shares in the last quarter. First Pacific Financial boosted its stake in Guardant Health by 33.1% during the first quarter. First Pacific Financial now owns 559 shares of the company’s stock worth $52,000 after acquiring an additional 139 shares in the last quarter. Xponance LLC grew its holdings in Guardant Health by 2.1% in the fourth quarter. Xponance LLC now owns 9,630 shares of the company’s stock worth $984,000 after purchasing an additional 199 shares during the period. Finally, Danske Bank A S grew its holdings in Guardant Health by 20.0% in the fourth quarter. Danske Bank A S now owns 1,200 shares of the company’s stock worth $123,000 after purchasing an additional 200 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

GH has been the subject of several research analyst reports. TD Cowen reiterated a “buy” rating on shares of Guardant Health in a report on Thursday, May 21st. Barclays boosted their target price on Guardant Health from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Mizuho upped their target price on Guardant Health from $135.00 to $175.00 and gave the company an “outperform” rating in a report on Monday, June 8th. BTIG Research set a $160.00 price target on Guardant Health and gave the stock a “buy” rating in a research note on Wednesday, May 27th. Finally, Wolfe Research initiated coverage on shares of Guardant Health in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $150.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $141.95.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.